Form 8-K

8-K — LifeMD, Inc.

Accession: 0001493152-26-029503

Filed: 2026-06-22

Period: 2026-06-22

CIK: 0000948320

SIC: 8011 (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000948320

2026-06-22

0000948320

LFMD:CommonStockParValue0.01PerShareMember

2026-06-22

0000948320

LFMD:Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember

2026-06-22

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 22, 2026

LIFEMD,

INC.

(Exact

name of Registrant as specified in its charter)

Delaware

001-39785

76-0238453

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

236

Fifth Avenue, Suite 400

New

York, NY 10001

(Address

of principal executive offices, including zip code)

(866)

351-5907

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any

of the following provisions:

☐

Written

communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.01 per share

LFMD

The

Nasdaq Global Market

8.875%

Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share

LFMDP

The

Nasdaq Global Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

June 22, 2026, LifeMD, Inc. (the “Company” or “LifeMD”) announced a strategic co-marketing collaboration supporting

a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection, the only FDA-approved once-weekly subcutaneous

testosterone auto-injector. The program will launch in July 2026 and will initially be available in 37 states.

The

Company entered into a Master Services Agreement and Statement of Work, as well as Specialty Pharmacy Services Agreements, with Antares

Pharma, Inc., a subsidiary of Halozyme, Inc., in furtherance of the strategic co-marketing collaboration. Under these agreements, the

Company will serve as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program. Patients accessing the program

will be evaluated by licensed clinicians through the Company’s affiliated medical group, and the Company’s pharmacy will

serve as the preferred dispensing pharmacy for the program, shipping XYOSTED directly to patients’ homes. The parties will collaborate

on, and jointly invest in, consumer education and promotional initiatives designed to expand awareness of testosterone deficiency and

of the program itself.

The

parties will establish a joint steering committee to provide strategic oversight and governance of the project and the parties’

respective obligations, including quarterly proposal, review and approval of co-funded marketing investments. Failure to meet budgeted

marketing investments for two consecutive quarters will give either party the right, but not the obligation, to terminate the Statement

of Work.

The

agreements have an initial term of three years with automatic renewal for successive one-year periods unless either party provides 90

days’ written notice of non-renewal. The agreements contain customary representations, warranties and covenants by each of the

parties, and indemnification provisions under which the parties have agreed, subject to certain limitations, to indemnify each other

against certain liabilities.

June 22, 2026, the Company issued a press release announcing the strategic co-marketing collaboration. A copy of the Company’s

press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The

Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including the press release,

that is required to be disclosed solely by reason of Regulation FD. The Company undertakes no duty or obligation to publicly update or

revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes

is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or

through other public disclosure.

The

information provided under this Item 7.01 of this Current Report on Form 8-K, including the press release, is “furnished”

and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed

incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall

be expressly set forth by specific reference in such filing.

Cautionary

Statements Regarding Forward-Looking Information

This

Current Report on Form 8-K, including the press release, contains forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995, including, without limitation, statements regarding the expected launch timing, scope, pricing, and benefits

of the XYOSTED self-pay program; the number of states in which the program will be available and any potential expansion; the parties’

planned promotional and consumer education initiatives; expected patient demand and access; and the anticipated benefits of the collaboration

to patients and to each company. Words such as “expect,” “believe,” “will,” “designed to,”

“anticipate,” and similar expressions identify forward-looking statements. These statements are based on current expectations

and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related

to the commercial launch and adoption of the program, changes in federal or state laws governing telehealth prescribing of controlled

substances, regulatory and compliance requirements applicable to telehealth, pharmacy, and pharmaceutical promotion, and the other risks

described in each company’s filings with the Securities and Exchange Commission, including LifeMD’s and Halozyme’s

most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Neither company undertakes any obligation to update

forward-looking statements except as required by law.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release dated June 22, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

LIFEMD, INC.

Dated:

June

22, 2026

By:

/s/

Eric Yecies

Chief

Legal Officer and General Counsel

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

LifeMD

Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Landmark

agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement

with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states

Companies

to collaborate on consumer education and promotional initiatives to expand awareness of hypogonadism and convenient, transparent access

to FDA-approved treatment

NEW

YORK and SAN DIEGO, June 22, 2026 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and specialty care

today announced a strategic co-marketing collaboration supporting a direct-to-patient self-pay program for XYOSTED® (testosterone

enanthate) injection, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The program will launch in July 2026

and will initially be available in 37 states.

Under

agreements entered into with Halozyme’s wholly owned subsidiary, Antares Pharma, Inc., LifeMD will serve as the exclusive telehealth

co-marketing partner for the XYOSTED self-pay program. Patients accessing the program will be evaluated by licensed clinicians through

LifeMD’s independent, affiliated medical group, and LifeMD’s pharmacy will serve as the preferred dispensing pharmacy for

the program, shipping XYOSTED directly to appropriate patients’ homes. The companies will collaborate on, and jointly invest in,

consumer education and promotional initiatives designed to expand awareness of testosterone deficiency and of the program itself.

Testosterone

deficiency, or hypogonadism, affects millions of American men, yet many go undiagnosed or untreated due to fragmented care, inconvenient

treatment options, and unpredictable out-of-pocket costs. Life MD’s platform is designed to remove those barriers by combining

clinically appropriate virtual evaluation, lab-based diagnosis, ongoing clinical support, and access to home delivery of an FDA-approved

therapy at a transparent, all-inclusive price of approximately $249 per month — covering both medication and care, with no insurance

required. XYOSTED is self-administered once weekly using a pre-filled auto-injector, with 99.4% of injections reported to be pain-free

in its pivotal clinical study.1

“This

is a landmark collaboration between a virtual care company and a pharmaceutical manufacturer, and we believe it represents the future

of how branded medicines reach patients,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. “Millions

of men suffer from low testosterone and never receive guideline-based care because the path to treatment is too fragmented and too expensive.

By pairing LifeMD’s nationwide clinical and pharmacy infrastructure with an option for patients to receive the only FDA-approved,

virtually painless weekly testosterone auto-injector, we are giving men a single, seamless way to get diagnosed, treated, and supported

— at one transparent monthly price that includes their care, delivered to their door. LifeMD is proud to support increased access

to hypogonadism treatment through this program, and we believe this collaboration will become the blueprint for how pharma and virtual

care work together.”

“XYOSTED

is a proven therapy. Our collaboration with LifeMD is about making sure the right patients can actually access it,” said Dr. Helen

Torley, President and Chief Executive Officer of Halozyme. “LifeMD has built one of the best virtual care platforms in the country.

Together, we’re redefining how patients access treatment.”

150 patients entered the one-year trial; 99.4% of injections were reported to be pain free. Injection site reactions, including bruising,

bleeding, redness, and hardness, were reported in 12.7% of patients who received XYOSTED for up to 1 year in the trial. No patients

discontinued XYOSTED because of injection site reactions.

Through

the program, men seeking care for symptoms of testosterone deficiency will be able to complete a virtual consultation with a licensed

clinician, obtain laboratory testing confirming a diagnosis of hypogonadism, and — where clinically appropriate — receive

XYOSTED shipped directly from LifeMD’s pharmacy with ongoing clinical follow-up, dose management, and refill support, all included

in the monthly program price. At launch, the program will be available to self-pay patients in eligible states. We plan to expand both

to patients who want to use their insurance for care and medication, as well as into additional states as telehealth prescribing of controlled

substances permits.

About

XYOSTED®

(testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated

with a deficiency or absence of endogenous testosterone. Approved by the FDA in 2018, XYOSTED is the first and only once-weekly subcutaneous

testosterone auto-injector. Limitations of use: safety and efficacy of XYOSTED in males less than 18 years old have not been established,

and safety and efficacy in adult males with “age-related hypogonadism” have not been established. See additional Important

Safety Information below.

About

LifeMD

LifeMD®

is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized

treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone

therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art

affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information,

please visit LifeMD.com.

Cautionary

Note Regarding Forward-Looking Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including,

without limitation, statements regarding the expected launch timing, scope, pricing, and benefits of the XYOSTED self-pay program; the

number of states in which the program will be available and any potential expansion; the parties’ planned promotional and consumer

education initiatives; expected patient demand and access; and the anticipated benefits of the collaboration to patients and to each

company. Words such as “expect,” “believe,” “will,” “designed to,” “anticipate,”

and similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions and are

subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the commercial launch

and adoption of the program, changes in federal or state laws governing telehealth prescribing of controlled substances, regulatory and

compliance requirements applicable to telehealth, pharmacy, and pharmaceutical promotion, and the other risks described in each company’s

filings with the Securities and Exchange Commission, including LifeMD’s and Halozyme’s most recent Annual Reports on Form

10-K and subsequent Quarterly Reports on Form 10-Q. Neither company undertakes any obligation to update forward-looking statements except

as required by law.

IMPORTANT

SAFETY INFORMATION AND INDICATIONS

CONTRAINDICATIONS

XYOSTED

is contraindicated in:

● Men

with carcinoma of the breast or known or suspected carcinoma of the prostate.

● Women

who are pregnant. Testosterone can cause virilization of the female fetus when administered

to a pregnant woman.

● Men

with known hypersensitivity to XYOSTED or any of its ingredients (testosterone enanthate

and sesame oil).

WARNINGS

AND PRECAUTIONS

● Polycythemia—Increases

in hematocrit, reflective of increases in red blood cell mass, may require discontinuation

of XYOSTED. Check that hematocrit is not elevated prior to initiating XYOSTED. Evaluate hematocrit

approximately every 3 months while the patient is on XYOSTED. If hematocrit becomes elevated,

stop XYOSTED until the hematocrit decreases to an acceptable level. If XYOSTED is restarted

and again causes hematocrit to become elevated, stop XYOSTED permanently. An increase in

red blood cell mass may increase the risk of thromboembolic events.

● Venous

Thromboembolism (VTE)—There have been post-marketing reports of venous thromboembolic

events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using

testosterone products, such as XYOSTED.

the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE)

Study, a randomized, double-blind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, topical testosterone

gel was associated with a numerically higher incidence of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE events (0.9% vs

0.5%).

Evaluate

patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness

of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with XYOSTED and initiate appropriate workup and

management.

● Worsening

of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer—Patients

with BPH treated with androgens are at an increased risk of worsening of signs and symptoms

of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with

androgens may be at an increased risk for prostate cancer. Evaluate patients for prostate

cancer prior to initiating and during treatment with androgens.

·● Blood

Pressure Increase—XYOSTED can increase blood pressure. Ambulatory blood pressure

monitoring (ABPM) demonstrated XYOSTED increased systolic/diastolic BP by an average of 3.9/1.5

mmHg from baseline after 12 weeks of treatment in clinical trials. In patients with hypertension

on antihypertensive therapy, XYOSTED increased the mean systolic/diastolic BP by 3.9/1.3

mm Hg from baseline.

The

CV risk associated with topical testosterone gel was evaluated in TRAVERSE, a randomized, double-blind, placebo-controlled, CV outcomes

study in men with a history of CV disease or multiple CV risk factors. In TRAVERSE, topical testosterone gel increased mean systolic

blood pressure by 1.0 mm Hg from baseline to 36 months, whereas a mean decrease from baseline of 0.5 mm Hg was observed in the placebo

group at this timepoint, for a mean between-group difference of 1.5 mm Hg. However, the incidences of major adverse cardiovascular events

(MACE), including cardiovascular death, non-fatal myocardial infarction [MI] and non-fatal stroke, were similar between treatment groups

(7% for topical testosterone gel vs 7.3% for placebo).

Monitor

blood pressure periodically in men using XYOSTED, especially men with hypertension. XYOSTED is not recommended for use in patients with

uncontrolled hypertension.

● Abuse

of Testosterone and Monitoring of Serum Testosterone Concentrations—Testosterone

has been subject to abuse, typically at doses higher than recommended for the approved indication

and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse

can lead to serious cardiovascular and psychiatric adverse reactions.

testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone

levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious

adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone

and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.

● Not

for Use in Women—Due to lack of controlled studies in women and potential virilizing

effects, XYOSTED is not indicated for use in women.

● Potential

for Adverse Effects on Spermatogenesis—With large doses of exogenous androgens,

including XYOSTED, spermatogenesis may be suppressed through feedback inhibition of pituitary

follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen

parameters including sperm count. Patients should be informed of this possible risk when

deciding whether to use or to continue to use XYOSTED.

● Hepatic

Adverse Effects—Prolonged use of high doses of orally active 17-alpha-alkyl androgens

(e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis

hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be

a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone

enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic

adenomas. XYOSTED is not known to produce these adverse effects. Nonetheless, patients should

be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If

these occur, promptly discontinue XYOSTED while the cause is evaluated.

● Edema—Androgens,

including XYOSTED, may promote retention of sodium and water. Edema with or without congestive

heart failure may be a serious complication in patients with preexisting cardiac, renal,

or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

● Gynecomastia—Gynecomastia

may develop and may persist in patients being treated for hypogonadism.

● Sleep

Apnea—Treatment with testosterone products, including XYOSTED, may potentiate sleep

apnea in some patients, especially those with risk factors such as obesity or chronic lung

disease.

● Lipid

Changes—Changes in the serum lipid profile may require dose adjustment of lipid

lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically,

particularly after starting testosterone therapy.

● Hypercalcemia—Androgens,

including XYOSTED, should be used with caution in cancer patients at risk of hypercalcemia

(and associated hypercalciuria). Monitor serum calcium concentrations regularly during treatment

with XYOSTED in these patients.

● Decreased

Thyroxine-binding Globulin—Androgens, including XYOSTED, may decrease concentrations

of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased

resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however,

and there is no clinical evidence of thyroid dysfunction.

● Risk

of Depression and Suicide—Depression and suicidal ideation and behavior, including

completed suicide, have occurred during clinical trials in patients treated with XYOSTED.

Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation

or behavior, new onset or worsening depression, anxiety, or other mood changes.

ADVERSE

REACTIONS

● The

safety of XYOSTED was evaluated in 2 clinical studies in a total of 283 men who received

weekly subcutaneous doses for up to 1 year. All patients were started on 75 mg weekly, then

the dose was titrated to 50 mg or 100 mg weekly, as needed, to achieve pre-dose total testosterone

concentrations of ≥350 ng/dL and <650 ng/dL.

● The

most commonly reported adverse reactions (>5%) were: hematocrit increased, hypertension,

PSA increased, injection site bruising, and headache.

DRUG

INTERACTIONS

● Insulin—Changes

in insulin sensitivity or glycemic control may occur in patients treated with androgens.

In diabetic patients, the metabolic effects of androgens may decrease blood glucose and,

therefore, may necessitate a decrease in the dose of anti-diabetic medication.

● Oral

Anticoagulants—Changes in anticoagulant activity may be seen with androgens, therefore,

more frequent monitoring of international normalized ratio (INR) and prothrombin time are

recommended in patients taking warfarin, especially at the initiation and termination of

androgen therapy.

● Corticosteroids—The

concurrent use of testosterone with corticosteroids may result in increased fluid retention

and requires careful monitoring, particularly in patients with cardiac, renal or hepatic

disease.

● Medications

that May Also Increase Blood Pressure—Some prescription medications and nonprescription

analgesic and cold medications contain drugs known to increase blood pressure. Concomitant

administration of these medications with XYOSTED may lead to additional increases in blood

pressure.

USE

IN SPECIFIC POPULATIONS

● Pregnancy—XYOSTED

is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm

when administered to a pregnant woman based on data from animal studies and its mechanism

of action. Exposure of a female fetus to androgens may result in varying degrees of virilization.

In animal developmental studies, exposure to testosterone in utero resulted in hormonal and

behavioral changes in offspring and structural impairments of reproductive tissues in female

and male offspring. These studies did not meet current standards for nonclinical development

toxicity studies.

● Lactation—XYOSTED

is not indicated for use in females.

● Females

and Males of Reproductive Potential - During treatment with large doses of exogenous

androgens, including XYOSTED, spermatogenesis may be suppressed through feedback inhibition

of the hypothalamic-pituitary-testicular axis. Reduced fertility is observed in some men

taking testosterone replacement therapy. The impact on fertility may be irreversible.

● Pediatric

Use—Safety and effectiveness of XYOSTED in pediatric patients less than 18 years

old have not been established. Improper use may result in acceleration of bone age and premature

closure of epiphyses.

● Geriatric

Use—There have not been sufficient numbers of geriatric patients in controlled

clinical studies with XYOSTED to determine whether efficacy or safety in those over 65 years

of age differs from younger subjects. Of the 283 patients enrolled in the 6-month and 1-year

efficacy and safety clinical study utilizing XYOSTED, 49 (17%) were over 65 years of age.

Additionally, there are insufficient long-term safety data in geriatric patients to assess

the potentially increased risk of cardiovascular disease and prostate cancer. Geriatric patients

treated with androgens may also be at risk for worsening of signs and symptoms of BPH.

DRUG

ABUSE AND DEPENDENCE

● XYOSTED

contains testosterone enanthate, a Schedule III controlled substance in the Controlled Substances

Act.

● Abuse

and misuse of testosterone are seen in male and female adults and adolescents. Testosterone,

often in combination with other anabolic androgenic steroids, may be abused by athletes and

bodybuilders.

● Serious

adverse reactions have been reported in individuals who abuse anabolic androgenic steroids,

and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive

heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations,

including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility,

and aggression.

● The

following adverse reactions have been reported in men: transient ischemic attacks, convulsions,

hypomania, irritability, dyslipidemia, testicular atrophy, subfertility, and infertility.

● The

following adverse reactions have been reported in women: hirsutism, virilization, deepening

of voice, clitoral enlargement, breast atrophy, male pattern baldness, and menstrual irregularities.

● The

following adverse reactions have been reported in male and female adolescents: premature

closure of bony epiphyses with termination of growth, and precocious puberty.

● Withdrawal

symptoms can be experienced upon abrupt discontinuation in patients with addiction. Withdrawal

symptoms include depressed mood, major depression, fatigue, craving, restlessness, irritability,

anorexia, insomnia, decreased libido, and hypogonadotropic hypogonadism. Drug dependence

in individuals using approved doses for approved indications have not been documented.

XYOSTED

INDICATIONS AND USAGE

● XYOSTED

(testosterone enanthate) injection is an androgen indicated for testosterone replacement

therapy in adult males for conditions associated with a deficiency or absence of endogenous

testosterone.

● Primary

hypogonadism (congenital or acquired)

● Hypogonadotropic

hypogonadism (congenital or acquired)

LIMITATIONS

OF USE

● Safety

and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established

Safety

and efficacy of XYOSTED in males less than 18 years old have not been established

Investor

Contact

investors@lifemd.com

Media

Contact

press@lifemd.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (15195 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jun. 22, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 22, 2026

Entity File Number

001-39785

Entity Registrant Name

LIFEMD,

INC.

Entity Central Index Key

0000948320

Entity Tax Identification Number

76-0238453

Entity Incorporation, State or Country Code

Entity Address, Address Line One

236

Fifth Avenue

Entity Address, Address Line Two

Suite 400

Entity Address, City or Town

New

York

Entity Address, State or Province

Entity Address, Postal Zip Code

10001

City Area Code

(866)

Local Phone Number

351-5907

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock, par value $0.01 per share

Title of 12(b) Security

Common

Stock, par value $0.01 per share

Trading Symbol

LFMD

Security Exchange Name

NASDAQ

8.875% Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share

Title of 12(b) Security

8.875%

Series A Cumulative Perpetual Preferred Stock, par value $0.0001 per share

Trading Symbol

LFMDP

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=LFMD_Sec8.875SeriesCumulativePerpetualPreferredStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: